Seasonal Allergy Guidelines 2026: What's Changed and What It Means for You

Why This Matters Right Now

If your seasonal allergies have felt worse in recent years, you are not imagining it. Pollen seasons are starting earlier, lasting longer, and producing more allergen than they did when most current allergy treatments were first studied.^[4]

About 1 in 4 US adults and 1 in 5 children live with seasonal allergic rhinitis — tens of millions of people whose treatment plans were built on guidance that hasn't been fully updated in over a decade.

In April 2026, the Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, with the European Academy of Allergy and Clinical Immunology (EAACI), published the most significant update to allergy treatment guidance since 2010.^[1] The shifts are practical: a new first-line therapy for moderate to severe symptoms, clearer preferences among nasal sprays, and a strong push away from a category of medication many patients still rely on.

The Climate Reality Behind Worsening Symptoms

Allergy treatment guidelines have to keep up with the allergens themselves — and US allergen exposure has shifted measurably.

Climate Central's 2026 analysis of 198 US cities found pollen seasons are now 21 days longer on average than they were in 1970, with 173 of those cities showing a lengthening trend.^[4] The Northwest has gained 31 days, the Southwest 22, the Southeast 19, and the Northeast 17. Total US pollen emissions are projected to climb 16% to 40% by the end of the century as warmer temperatures and higher carbon dioxide levels push plants — especially grasses and ragweed — to produce more pollen for longer windows.^[4]

A 2025 review in Laryngoscope covering 30 studies found 16 reporting longer pollen seasons linked to climate change and 4 documenting rising allergic rhinitis healthcare visits.^[5] The practical takeaway: the same allergic person now has more days of symptoms each year, so treatment plans need to last longer and start earlier.

What's New in the 2026 ARIA Guidelines

The new guideline was developed using GRADE methodology. Several recommendations carry meaningful implications for everyday treatment.^[1]

Combination INAH+INCS sprays move to first-line

For moderate to severe seasonal allergic rhinitis where a single agent is unlikely to control symptoms, the guidelines now suggest a combination intranasal antihistamine and corticosteroid spray over either INCS or intranasal antihistamine alone. Azelastine-fluticasone is the best-studied combination. Patients on combination sprays show faster onset of relief and higher satisfaction than those on monotherapy.^[1]

INCS still beats oral antihistamines for nasal symptoms

For mild seasonal allergic rhinitis, or as a step-down from combination therapy, intranasal corticosteroid alone remains preferred over oral antihistamines for nasal symptoms. The evidence shows clear superiority on stuffiness, runny nose, and quality of life.^[2]

Specific INCS preferences emerge

A 2024 network meta-analysis of 151 primary studies, published in the Journal of Allergy and Clinical Immunology, identified azelastine-fluticasone, fluticasone furoate, and fluticasone propionate as the agents with the highest probability of producing moderate to large improvements in total nasal symptom scores and quality of life for seasonal allergic rhinitis.^[3] Clinicians following the new guidelines now favor these over older options like beclomethasone, budesonide, ciclesonide, mometasone, and triamcinolone when an INCS is appropriate.

A strong recommendation against routine intranasal decongestants

The guidelines come down hard on long-term use of intranasal decongestants. Adding a decongestant spray to an INCS produced no additional efficacy benefit but increased adverse events, including rebound congestion and rhinitis medicamentosa.^[1] Long-term use is now strongly discouraged.

Why Intranasal Beats Oral for Most Symptoms

The 2017 meta-analysis still cited in the new guidelines pooled five randomized trials and 990 patients comparing intranasal corticosteroids with oral antihistamines.^[2] INCS were superior for total nasal symptoms (standardized mean difference -0.70), nasal obstruction (-0.56), and disease-specific quality of life (mean difference -0.90).

One area where the comparison was a wash: ocular symptoms. For itchy, watery eyes, oral antihistamines and intranasal sprays performed similarly. Modern non-sedating oral options — loratadine, cetirizine, fexofenadine — remain useful when eye symptoms are prominent or when patients need breakthrough coverage on top of a daily nasal spray.

The Long Game: Sublingual Immunotherapy

For patients with persistent moderate to severe seasonal allergies and confirmed allergens on testing, the 2026 guidance gives more weight to sublingual immunotherapy (SLIT) than past guidelines did. SLIT uses daily tablets or liquid drops under the tongue to gradually retrain the immune system's response to specific allergens.

A real-world study of 74,126 patients on SLIT tablets found an 18.8% reduction in allergic rhinitis symptomatic medication use compared with a control group, plus roughly a 30% reduction in asthma development risk during treatment and 40% post-treatment.^[7] The benefits persisted for up to 6 years after stopping therapy. A 2025 meta-analysis in Frontiers in Allergy covering 25 randomized trials and over 1,800 patients confirmed that SLIT significantly reduces both symptom and medication scores across grass, dust mite, tree, and weed allergens.^[8]

SLIT is best suited for patients with persistent moderate to severe symptoms confirmed by testing, those with asthma comorbidity, and pediatric patients where early intervention may slow disease progression. No injections required.

Thunderstorm Asthma: A New Concern

A 2025 Wichita study presented at the American College of Allergy, Asthma and Immunology meeting analyzed 4,439 asthma emergency department visits. About 14% of those visits clustered on just 38 thunderstorm days — only 2% of the calendar year.^[6] Average daily admissions were nearly six times higher on storm days than non-storm days.

The proposed mechanism: thunderstorm updrafts loft pollen grains into clouds, where humidity and electrical activity rupture them into smaller fragments that penetrate deeper into the airways than intact pollen and can trigger bronchospasm — even in people who normally only experience nasal symptoms. Allergic rhinitis is an independent risk factor for thunderstorm asthma.

If you have seasonal allergies and any history of asthma symptoms, staying indoors during thunderstorms in your local pollen season is a low-cost protective step, and your asthma action plan should address storm preparedness.

What This Means for You

Translating new guidelines into real treatment decisions takes a few practical steps.

If you have moderate to severe seasonal symptoms: a combination intranasal antihistamine + corticosteroid spray is now considered the most effective starting option. It works faster than a single-agent spray and produces higher satisfaction in published trials.

If you've been on a single nasal spray and it's not enough: combination products represent an evidence-backed upgrade. Talk to your physician about transitioning rather than adding more medications on top.

If you're using a decongestant nasal spray long-term: this is no longer recommended. Rebound congestion is real, and the data does not support adding decongestants to a corticosteroid spray. A planned taper with physician guidance prevents withdrawal symptoms.

If your symptoms are persistent and confirmed by allergy testing: ask whether sublingual immunotherapy makes sense for you. It is the only option on the table that can change the course of the disease itself.

Start earlier in the season: beginning treatment about 2 weeks before your trigger season is more effective than reactive use after symptoms hit.

Telehealth visits work well for allergy management. You can review symptoms, optimize your current regimen, discuss SLIT eligibility, and get prescriptions adjusted without a trip to the office. If you'd like a structured review of your current allergy plan against the new guidelines, a virtual visit is a practical place to start.